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Abstract: Non-alcoholic fatty liver disease (NAFLD) confers an increased risk of cardiovascular
diseases. NAFDL is associated with atherogenic dyslipidemia, inflammation and renin-angiotensin
system (RAS) imbalance, which in turn lead to atherosclerotic lesions. In the present study, the impact
of a natural dietary supplement (NDS) containing Curcuma longa, silymarin, guggul, chlorogenic
acid and inulin on NAFLD and atherosclerosis was evaluated, and the mechanism of action was
examined. C57BL/6 mice were fed an HFD for 16 weeks; half of the mice were simultaneously
treated with a daily oral administration (os) of the NDS. NAFLD and atherogenic lesions in aorta
and carotid artery (histological analysis), hepatic expression of genes involved in the NAFLD (PCR
array), hepatic angiotensinogen (AGT) and AT1R mRNA expression (real-time PCR) and plasma
angiotensin (ANG)-II levels (ELISA) were evaluated. In the NDS group, steatosis, aortic lesions
or carotid artery thickening was not observed. PCR array showed upregulation of some genes
involved in lipid metabolism and anti-inflammatory activity (Cpt2, Ifng) and downregulation of
some genes involved in pro-inflammatory response and in free fatty acid up-take (Fabp5, Socs3).
Hepatic AGT, AT1R mRNA and ANG II plasma levels were significantly lower with respect to the
untreated-group. Furthermore, NDS inhibited the dyslipidemia observed in the untreated animals.
Altogether, these results suggest that NDS prevents NAFLD and atherogenesis by modulating the
expression of different genes involved in NAFLD and avoiding RAS imbalance.
Keywords: non-alcoholic fatty liver disease; atherogenic lesions; diet-induced obesity; natural dietary
supplement; renin-angiotensin system imbalance; Profiler PCR array
1. Introduction
Non-alcoholic fatty liver disease (NAFLD) is the most frequent hepatic disorder in developed
countries and may lead to steatohepatitis, cirrhosis and liver cancer. NAFLD is also considered
the hepatic component of metabolic syndrome (MetS) because it is associated with atherogenic
dyslipidemia, obesity and type 2 diabetes (T2DM) [1]. The precise mechanism of the onset and
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progression of NAFLD remains unclear although increased fatty acid syntheses, oxidative stress and
inflammation may play a fundamental role [2].
Emerging evidence suggests that angiotensin (ANG) II, a pro-oxidant cytokine, synthesized
mainly from the hepatic precursor angiotensinogen (AGT), may have a relevant importance in the
pathogenesis of NAFLD by generating reactive oxygen species and regulating the production of
pro-inflammatory mediators [3]. Patients with NAFLD present elevated ANG II levels [4,5], and
animals with liver steatosis show increased hepatic expression of AGT, AGT II and ANG II type 1
receptor (AT1R) [6,7]. The renin-angiotensin system (RAS) and its primary mediator ANG II have also
a direct influence on the progression of the atherosclerotic process via effects on endothelial function,
inflammation, fibrinolytic balance and plaque stability [8]. Increasing clinical evidence supports a
strong association between NAFLD and cardiovascular diseases (CVD), which represents the principal
cause of death in NAFLD patients, more so than liver-related complications [9,10]. Patients with
NAFLD have an altered flow-mediated vasodilatation and increased carotid-artery intimal medial
thickness, two reliable markers of subclinical atherosclerosis [11]. Therefore, the involvement of
AGT II in NAFLD pathogenesis and in atherosclerotic plaque formation may provide one of the
possible links between NAFLD and accelerated atherogenesis. Accordingly, the use of RAS blockers
seems to be potentially useful as a therapeutic approach against NAFLD [12] and atherosclerosis [13].
To date, there is no single approved pharmacologic therapy to treat metabolic dysfunctions occurring
in obesity, such as NAFLD and related atherosclerosis. The backbone of therapy currently includes
lifestyle management to induce weight loss and therapeutic treatment to reduce cardiovascular risk or
hyperglycemia [14]. Recently, natural herbs have been the focus of many researches both because of
their safety and efficacy and because their potential bio-active ingredients could help to prevent or
treat obesity and the related metabolic disorders [15]. The natural dietary supplement (NDS) used in
this study contains extracts from Cynara scolymus (chlorogenic acid), Silybum marianum (silymarin),
Taraxacum officinale (inulin), Curcuma Longa (curcuma) and Commiphora mukul (guggul), plant extracts
that exert protective actions mainly towards the liver. Recent evidence has shown that the treatment
with the NDS exerts beneficial effects in patients with MetS, reducing anthropometric parameters and
total cholesterol levels, but the mechanism of action is still unknown [16].
This study aims to investigate whether the treatment with this NDS is able to prevent the
development of NAFLD and related atherosclerotic lesions in aorta and carotid artery in a mouse
model of diet-induced obesity (DIO). In order to investigate the mechanism of action of the natural
supplement, its ability to modulate the expression of some RAS components (AGT and AT1R mRNA
in liver and circulating concentration of AGT II) or of genes involved in NAFLD was examined.
In addition, the impact of the NDS treatment in the plasma lipid profile was also analyzed.
2. Materials and Methods
2.1. Animals
The procedures were performed in accordance with the conventional guidelines for animal
experimentation (Italian D.L. (Legislative Decree) No. 116 of 27 January 1992 and subsequent
variations) and the recommendations of the European Economic Community (86/609/ECC).
Male C57BL/6J (B6) mice, purchased from Harlan Laboratories (San Pietro al Natisone Udine,
Italy) at 4 weeks of age, were housed in a room with controlled temperature and dark-light cycles,
with free access to water and food. After acclimatization (1 week), the animals were weighed and
divided into two groups, both fed a high-fat diet (HFD) (PF4051/D, Mucedola, Milan, Italy) composed
of 60% of energy as fat, 20% protein and 20% carbohydrates, for 16 weeks.
It has been shown that these animals, consequent to an HFD, develop obesity, hyperglycemia [17],
hepatic steatosis [18], atherosclerosis [19] and neurodegeneration [20].
One group served as a control of obesity-related dysfunctions (n = 6, untreated group), and the
other one (n = 6, treated group) received, simultaneously to the HFD, a daily administration of NDS
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(0.9 mg/mouse) for 16 weeks. The dose given to the DIO mice was extrapolated from the human
dosage (1.6 g/day) and calculated on the basis of the average body weight (40 mg).
The NDS used in this study is, in Italy, commercialized under the name Kèpar® and was provided
by Rikrea® S.r.l. (Modica-RG, Italy). The main constituents of the NDS are plant-derived polyphenolic
compounds that are well known for their antioxidant and anti-inflammatory properties. In particular,
NDS consists of extract from five plant sources, and each extract was obtained from a different part of
the plant (Table 1).
Table 1. Ingredients of the natural dietary supplement (NDS) formulation.
Herbal Components Part Used Quantity/100 g
Cynara scolymus, e.s. tit. 2.5%
chlorogenic acid Leaf
35 g (extract)
0.87 g (Chlor. acid)









e.s. tit. 95% curcumin Rhizome
10 g (powder)
9.5 g (curcumin)




e.s. tit.: Dry extract titrated; Chlor. acid: Chlorogenic acid.
The tablets of the NDS (Kèpar, Batch No. SL0010) were ground by pestle and 9 mg of powder
dissolved in 200 µL of water and used as stock solution. The daily dose was freshly made up, by
diluting 1:10 the stock solution (0.9 mg/mouse in 20 µL), and was administered by oral gavaging. The
administrated dose contained: 0.09 mg of Curcuma, 0.057 mg of silymarin, 0.0135 mg of guggul lipids,
0.008 of chlorogenic acid and 0.002 mg of inulin. During the 16 weeks of the treatment, changes in
body weight and food-intake, determined by measuring the difference between the pre-weighed chow
and the weight of chow at intervals of 24 h [21], were periodically monitored and compared between
the two groups of animals. After 16 weeks of treatment, mice were sacrificed, and blood, liver, aorta
and carotid artery were immediately collected for subsequent analysis.
2.2. Histological Analysis
Aorta, carotid arteries and liver specimens excised from each hepatic lobe were fixed in 4%
formalin for 24 h. After this treatment, the tissues were dehydrated in alcohol and embedded
in paraffin wax. Paraffin histological sections (5 µm thick) were stained with hematoxylin and
eosin and observed using an automated Leica DM5000 B microscope (Leica, Milan, Italy) connected
to a high-resolution camera, Leica DC300 F (Leica, Milan, Italy). According to the Non-alcoholic
Steatohepatitis Clinical Research Network (NASH CRN) scoring system, steatosis was determined by
analyzing the morphology and percentage of lipid vesicles in hepatocytes [22].
2.3. Atherogenic Index (AIS)
The atherogenic index serum (AIS), which is the measure of the atherosclerotic lesion extent based
on serum lipids [23], was determined in all groups. The atherogenic index serum is calculated using
the formula AIS = total cholesterol (TC)/HDL [24].
2.4. Biochemical Analysis
Lipid profile was measured in mice fasted for 6 h with free access to water. After this time, the
mice were euthanized, and the blood was drawn by cardiac puncture and immediately transferred into
chilled tubes containing a final concentration of 1 mg/mL EDTA. Then, the samples were centrifuged
at 825 g for 10 min, and the obtained plasma was stored at −80 ◦C until analysis. Plasma triglyceride,
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cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL) levels and AST- and
ALT-serum concentrations were measured using the ILAB 600 Analyzer (Instrumentation Laboratory,
Bedford, Massachusetts).
2.5. Quantitative Real-Time qPCR
Total RNA from livers of treated and untreated obese mice were extracted using the RNEasy
Mini Kit (Qiagen, Milan, Italy). Two nanograms of RNA were used to synthesize the first strand
cDNA using the RT First-Strand kit (Qiagen, Milan, Italy). Synthesized cDNAs were amplified using
RT2 SYBR Green/ROX qPCR Mastermix (Qiagen, Milan, Italy) and StepOne Real-Time instrument
(Applied Biosystem, Foster City, CA, USA).
Gene expression analysis was performed using sequence primers for mice AGT, AT1R and β-actin
(SigmaLife Sciences, Milan, Italy). The primers were as follows: AGT forward 5’-GTA CAG ACA
GCA CCC TAC TT-3’, reverse 5’-TTG TTG AAG AGG CAC TGC AC-3’; AT1R forward 5’-GAC CAA
CTC AAC CCA GAA AAGC-3’, reverse 5’-CCT TTG TCG AAC CAC CACTA-3’; β-actin forward
5’-CGG GAT CCC CGC CCT AGG CAC CAG GGT-3’, reverse 5’-GGA ATT CGG CTG GGG TGT TGA
AGG TCT CAAA-3’. Each PCR reaction was amplified in triplicate, and levels of expression were
calculated after normalization to β-actin. On the basis of the Ct value (threshold cycle; the number of
reaction cycles after which fluorescence exceeds the defined threshold) of the examined gene and of
the internal control gene, the relative expression level of RNA was calculated according to the 2−∆∆Ct
approximation method.
2.6. RT2 Profiler PCR Array
Synthesized cDNAs from NDS-treated and NSD-untreated livers were added to 96-well reaction
plates of the Mouse Fatty Liver PCR Array (PAMM-157Z, SABiosciences, Qiagen, Milan, Italy)
according to the manufacturer's instructions. The array profiles the expression of 84 key genes involved
in the mechanisms of non-alcoholic fatty liver disease (NAFLD) and hepatic insulin resistance. The
reaction was performed by using a StepOne Real-Time instrument (Applied Biosystem, Foster City,
CA, USA). Analysis was performed using the spreadsheet provided by Qiagen Company, Milan, Italy.
2.7. Measurement of Circulating Levels of Angiotensin II
Quantification of plasma AGT II was carried out by the ELISA kit for mice (Enzo Life Sciences, Inc.
Farmingdale NY, USA) according to the manufacturer’s instructions. The experimental detection limit
of the analysis was 3.9 pg/mL.
2.8. Statistical Analyses
Results are shown as means ± the standard error of the mean (S.E.M.). The letter n indicates the
number of animals. Statistical analyses were performed using Prism Version 6.0 Software (Graph Pad
Software, Inc., San Diego, CA, USA). The comparison between the groups was performed by ANOVA
followed by Bonferroni’s post-test. A p-value ≤ 0.05 was considered statistically significant.
3. Results
3.1. The Natural Dietary Supplement Prevents the Development of NAFLD
At the end of the treatment, the untreated mice had greater mass gain compared to the animals
treated with NDS (Figure 1A), although no difference in the food intake was observed (Figure 1B).
Furthermore, the liver weight (Figure 1C) and ratio liver weight/body weight (Figure 1D) was higher
than the treated group. In the untreated mice, steatosis affected the liver gross appearance.
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Figure  1.  NDS  reduces  food  intake,  body  and  liver  weight  in  HFD  mice.  Effects  of  the  NDS 
treatment (0.9 mg/mouse) on body weight (A), food intake (B), liver weight (C) and the ratio of liver 
weight/body weight  (D),  in mice  fed  a  high‐fat  diet  (HFD).  Data  are  the means  ±  S.E.M.  (n  = 
6/group). * p ≤ 0.05. 
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was not affected by  fat accumulation  (Figure 2B), and  the histological analysis did not  reveal  the 
presence  of  steatosis  (Grade  0:  <5%),  but  only  the  presence  of  small  inclusions  of  lipids within 
hepatocytes  (Figure  2D–F).  Moreover,  in  agreement  with  the  liver  maintaining  the  lobular 
architecture, plasma AST and ALT were significantly  lower  in  treated mice  than  in  the untreated 
ones (Figure 2G).   
Figure 1. NDS reduces food intake, body and liver weight in HFD mice. Effects of the NDS treatment
(0.9 mg/mouse) on body weight (A), food intake (B), liver weight (C) and the ratio of liver weight/body
weight (D), in mice fed a high-fat diet (HFD). Data are the means ± S.E.M. (n = 6/group). * p ≤ 0.05.
In particular, the organ appeared enlarged with rounded edges. Moreover, it was pale-yellowish
color, friable with a gr asy texture attributable to the fat accumulation in the hepatic parenchyma
(Figur 2A). Hist l gically, the liver exhibited micro- and m cro-vesicul r steatosis (Grade I: >5%–33%)
in the perivenular area (Zone 3) and transition area (Zon 2) (Figure 2C) with focal infiltration of
polymorphonuclear cells (Figur 2E). Th hepatocytes showed a typic l foamy aspect; numerous
sm ll vacuoles c alesced and created cleared spac displacing the nucl us t the peri hery f the
cells (Fig re 2E). On the contrary, in the NDS-treat d mi e, th liver gross anatomy was not affected
by fat accumulation (Figure 2B), and the histological analysis did not reveal t presence of steatosis
(Grade 0: <5%), but only the presence of small inclusions of lipids within hepatocytes (Figure 2D–F).
Mor ov r, in agreement with the liver maintai ing the lobular architecture, plasma AST and ALT were
significantly lower in treated mice than in the untr at d ones (Figure 2G).
In addition, NDS-treated mice show d decreased triglyc rides, cholesterol and LDL and i cr s
HDL plasma levels in comparison with untreated animals (Figure 3).
3.2. The Natural Dietary Supplement Modulates the Expression of Genes Involved in NAFLD
To compare differences in the profile gene expression involved in NAFLD between the treated
and the untreated groups, we analyzed hepatic expression levels of 84 genes by PCR array analysis.
The position of the genes is signified in Table S1. In the hepatic tissue of treated mice, the expression
levels of 23 genes were affected (Table S1). Among these, nine were up- or down-regulated by more
than two-fold in comparison with the untreated animals (Figure 4A–C). In particular, NDS treatment
upregulates genes involved in lipid metabolism and anti-inflammatory mediators (Cpt2, Ifng), whereas
it downregulates genes involved in FFA up-take and in pro-inflammatory activity (Fabp5, Socs3).





images of gross anatomy and histological  cross‐sections of  liver  from NDS‐treated and untreated 
high‐fat diet  (HFD) mice. Liver morphologies of untreated HFD mice  (A)  and NDS‐treated HFD   
mice (B). Cross‐sections from untreated HFD mice (C,E) show micro‐ and macro‐vesicular steatosis 
(black  arrowhead)  with  polymorphonuclear  cell  infiltration  (black  arrow).  Histological 
Figure 2. NDS prevents NAFLD development in diet-induced obesity (DIO) animals. Representative
images of gross anatomy and histological cross-sections of liver from NDS-treated and untreated
high-fat diet (HFD) mice. Liver morph logies of untreated HFD mice (A) and NDS-treated HFD mice
(B). Cross-sections from u treated HFD mice (C,E) show micro- and macro-vesicular steatosis (black
arrowhe d) with polymorphonuclear cell infiltration (black arrow). Histological cross-secti ns from
NDS-treated HFD mice (D,F) show normal hepatocytes and maintaining of the lobular architecture.
Hematoxylin and eosin stain. Original magnification: (C,D) = ×200, (E,F) = ×400. (G) Plasma levels of
AST and ALT. Data are the mean values ± S.E.M. (n = 6/group). * p ≤ 0.05.
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tunica  media,  between  smooth  muscle  cells  and  elastic  lamina  (Figure  5A,B).  Carotid  arteries 
showed  an  increased  thickening  of  the  intima  characterized  by hyperplasia  and  the presence  of 
myocytes proliferating from the tunica media (Figure 5E,F). On the contrary, in NDS‐treated mice, 
neither  lesions  in aortic  root  (Figure 5C,D), nor carotid  intimal hyperplasia and alterations  in  the 
tunica media or adventitia (Figure 5G,H) were observed. 
Figure 4. NDS reduces the expression of genes involved in NAFLD pathogenesis. Livers of untreated
and treated high-fat diet (HFD) mice were used to perform the RNA for the PCR array analysis.
(A) Scatter plot of relative expression levels for each gene in mice samples (treated vs. untreated).
The figure depicts a log transformation plot of the relative expression level of each gene (2−∆Ct)
between untreated (x-axis) and treated mice (y-axis). The grey lines indicate a tw -fold change in e e
expression threshold. Red rings indicate upregulated genes; green rings indicate downregulated ge es.
(B) Histogram of s me up- and down-regulated genes with a greater than two-fold expression chang .
(C) Table of the nam and functions of the quantitative real-time PCR of th chosen genes.
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3.3. The Natural Dietary Supplement Prevents Atherosclerosis Development
Untreated mice showed atherosclerotic lesions with features of the earliest stages of the disease.
In fact, the observed lesions did not develop beyond the fatty-streak presence. The lesions of aorta
were confined to the aortic root and were characterized predominantly by lipid-laden areas in the
tunica media, between smooth muscle cells and elastic lamina (Figure 5A,B). Carotid arteries showed
an increased thickening of the intima characterized by hyperplasia and the presence of myocytes
proliferating from the tunica media (Figure 5E,F). On the contrary, in NDS-treated mice, neither lesions
in aortic root (Figure 5C,D), nor carotid intimal hyperplasia and alterations in the tunica media or
adventitia (Figure 5G,H) were observed.Nutrients 2017, 9, 492  9 of 15 
 
 
Figure  5.  NDS  prevents  the  development  of  atherosclerotic  lesions.  Representative  images  of 
histological cross‐sections of aortic arch and carotid artery  in high‐fat diet  (HFD) mice. The black 
arrow  (A,B) denotes  the prominent  fatty streak between elastic  laminae  (arrowhead)  in  the aortic 
root wall of untreated vs. treated (C,D) HFD mice. Carotid artery shows a hyperplasia of the intima 
(i)  in untreated HFD mice  (E,F). On  the  contrary, no  alterations of  carotid  artery  are detected  in 
treated HFD mice (G,H). a = tunica adventitia. s = smooth muscle cells. Hematoxylin and eosin stain. 
Original magnification: (A,C) = ×400; (B,D,F) and (H) = ×600; (E,G) = ×200. 
According  to  these  data,  the  AIS  was  significantly  higher  in  untreated  HFD‐fed  mice  in 
comparison with the treated obese mice (Figure 6). 
Figure 5. NDS prevents the development of atherosclerotic lesions. Representative images of
histological cross-sections of aortic arch and carotid artery in high-fat diet (HFD) mice. The black
arrow (A,B) denotes the prominent fatty streak between elastic laminae (arrowhead) in the aortic root
wall of untreated vs. treated (C,D) HFD mice. Carotid artery shows a hyperplasia of the intima (i) in
untreated HFD mice (E,F). On the contrary, no alterations of carotid artery are detected in treated HFD
mice (G,H). a = tunica adventitia. s = smooth muscle cells. Hematoxylin and eosin stain. Original
magnification: (A,C) = ×400; (B,D,F) and (H) = ×600; (E,G) = ×200.
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According to these data, the AIS was significantly higher in untreated HFD-fed mice in comparison





(0.9  mg/mouse)  on  AIS  of  high‐fat  diet  (HFD)‐fed  mice.  Data  are  the  mean  values  ±  S.E.M.   
(n = 6/group). * p ≤ 0.05. 
3.4. The Natural Dietary Supplement Reduces RAS Component Expression   
To  investigate whether variations  in the  levels of the RAS system are specifically involved  in 
the preventive effects of the natural supplement, we analyzed the hepatic mRNA levels of AGT and 
AT1R  by  quantitative  real‐time  PCR  and  circulating ANG  II  concentration  by  ELISA  assay.  In   
NDS‐treated mice,  hepatic AGT  and AT1R mRNA  expression  and  plasma ANG  II  levels were 
significantly lower in comparison with untreated mice (Figure 7A,B). 
 
Figure  7.  NDS  reduces  RAS  component  expression.  (A)  Expression  levels  of  AGT  and  AT1R 
mRNAs  in  liver  of  treated high‐fat diet  (HFD) mice  and  the untreated HFD  group,  by  real‐time 
RT‐PCR analysis. Data are  the mean values ± S.E.M.  (n = 3/group).  * p  ≤ 0.05.  (B) Effects of NDS 
treatment  (0.9 mg/mouse) on circulating  levels of angiotensin  II  in HFD mice, by ELISA. Data are 
the mean values ± S.E.M. (n = 6/group). * p ≤ 0.05. 
4. Discussion 
The  present  study  shows  that  the  natural  supplement,  here  utilized,  is  able  to  prevent  the 
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3.4. The atural ietary Supplement Reduces RAS Component Expression
To investigate whether variations in the l v ls of the RAS system are specifically involved in the
preventive effects of the natural s pplement, we analyzed the hepatic mRNA levels of AGT and AT1R
by quantitative real-time PCR and circulating ANG II concentration by ELISA assay. In NDS-treated
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determined by its ability to reduce the expression of the RAS components (AGT, AT1R and AGT II)
and modulate positively the expression of genes involved in NAFLD. The NDS also improves the lipid
profile, a typical obesity-related dysfunction.
In recent years, there has been an increasing interest in the use of plant extracts as potential
therapeutic agents. A mixture of natural products is used in various therapeutic areas obtaining a
number of interesting outcomes due to their synergistic effects [25]. The natural dietary supplement
used in this work, known as Képar, is used in the Italian market to treat liver discomfort, caused by
gallstones, cirrhosis and toxic agents. It is composed of several plant extracts (Curcuma, silymarin,
guggul, chlorogenic acid and inulin) that exert, at least individually, beneficial effects on different
components of MetS. Curcumin improves insulin resistance and dyslipidemia [26]; silymarin exerts
anti-inflammatory effects in animal models of NAFLD [27]; guggul lipids have been successfully used
in obesity and hypercholesterolemia [28]; and chlorogenic acid, as well as inulin, may improve lipidic
and glycidic metabolism [29,30]. In the present study, we have demonstrated that the diet natural
supplement is able to prevent body weight gain, hepatic fat accumulation, atherosclerotic lesions
development and dysregulation of lipidic metabolism. In fact, NDS-treated HFD mice showed a body
weight significantly lower than the untreated HFD animals, without any differences in the food intake.
This suggests that NDS prevents body mass gain by an independent mechanism from central control
of the feeding behavior.
It is interesting to note that our study represents the first experimental evidence for a preventive
role of the natural supplement against obesity-associated steatosis development. In fact, the liver of
treated obese mice did not show hepatomegaly or other histomorphological alterations; on the contrary,
the untreated group liver showed the presence of moderate micro- and macro-vesicular steatosis in
Zone 3, a zonal distribution highly associated with the severity of steatosis [31]. The positive impact of
NDS treatment, besides liver morphology, was also observed on the hepatic function, as suggested by
the reduced ALT and AST plasma levels in treated-obese animals compared to the untreated group.
In addition, the results showed that plasma triglycerides and LDL were lower and HDL higher in
treated HFD animals in comparison to the untreated mice, demonstrating that NDS exerts beneficial
effects on lipid metabolism and, consequently, on cardiovascular functions [32].
In order to examine the mechanism by which NDS prevents NAFLD, we also analyzed and
compared the hepatic expression of genes involved in NAFLD pathogenesis in treated vs. untreated
animals. For the first time, it was demonstrated that NDS is able to modulate different signaling
pathways involved in de novo hepatic lipogenesis, lipid oxidation and inflammatory responses.
In fact, in NDS-treated liver, genes involved in fatty acid turnover (such as Fabp1 and Cpt2) and
anti-inflammatory activity (Ifng) were upregulated, while genes involved in FFA uptake (Fabp5),
lipogenesis (Scd1) and inflammation (Socs3) were downregulated. The increased level of Cpt-2 and
Fabp-1 provides an explanation of the reduced hepatic lipid depots observed in the NDS-treated
liver. Cpt-2 is involved in beta-oxidation and Fabp-1 in the rapid removal of fatty acid in the
oxidative organelles [33]. Downregulation of Fabp5 and Scd1 also contributes to preventing hepatic
lipid accumulation, as Fabp5 leads to the fatty acid uptake [34] and Scd1 converts saturated FA to
monounsaturated FA, the major substrates necessary for the synthesis of other lipids [35]. On the
other hand, Scd1 knockout mice result in being resistant to the development of obesity and hepatic
steatosis [36], and the fatty livers of ob/ob mice show increased Scd1 expression [37].
Microarray analysis also showed that the treatment with the natural supplement is able to
modulate the expression of factors involved in the inflammatory process. In particular, the liver of
treated HFD mice showed upregulation of Ifng, a protective mediator against the liver inflammatory
process [38], and a very strong downregulation of Socs3, usually overexpressed in inflamed steatotic
liver [39], providing a molecular basis for the protective role of the NDS in the HFD liver.
It is well known that NAFLD shares many risk factors with cardiovascular diseases, implying
a close relationship between NAFLD and adverse cardiovascular events, such as hypertension and
atherosclerosis [9]. Accordingly, we analyzed the impact of NDS treatment on the development of
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atherogenic lesions in our animal models. Our results showed that no atherosclerotic lesions were
present in the vessels of NDS-treated obese mice. On the contrary, early hallmarks of atherosclerosis
were highlighted in the untreated-HFD group. In fact, in agreement with Whitman’s report [40],
we observed “fatty streak-type” lesions in the aortic root, representative of foam cells, which are
lipid-laden macrophages. We also observed carotid artery intimal-medial wall thickening. Additionally,
AIS, a measure of the atherosclerotic lesion extent based on serum lipid concentration [23,24], was
significantly lower in NDS-treated animals compared with untreated mice, suggesting a preventive
action of the natural supplement on atherogenesis development. Therefore, the improvement of the
lipid profile could explain the absence of lesions in the NDS-treated animals. Different mechanisms
explain the increased risk of cardiovascular events in patients with NAFLD. In fact, besides the
proatherogenic lipid profile, the disease is associated with an increased production of pro-inflammatory
cytokines [41,42] and RAS imbalance. Patients with NAFLD present elevated circulating levels of ANG
II and over-activation of intrahepatic RAS [4,5]. Our results showed that in the liver of NDS-treated
obese mice, angiotensinogen and AT1R mRNA were significantly decreased, as well as the circulating
levels of ANG II, suggesting that the treatment with the natural supplement protects from NAFLD
and atherogenesis by preventing RAS imbalance.
5. Conclusions
In conclusion, the natural dietary supplement (Kèpar) is effective in protecting against the
development of NAFLD and atherosclerotic lesions in obesity conditions. The NDS prevents liver fat
accumulation, development of atherosclerotic lesions and improves hyperlipidemia. These beneficial
effects seem to be mediated by the ability of the natural supplement to modulate the expression of
different genes involved in NAFLD and to prevent the imbalance of RAS components.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/9/5/492/s1:
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Acknowledgments: This work was supported by a grant from Rikrea© (Agreement STEBICEF-Rikrea, N.3252,
11-07-2014). The Rikrea fund covered publication charges. The authors thank Pierluigi Rosa for his contribution to
the idea of study.
Author Contributions: A.A. conceived of the idea, designed the study, performed some of the experiments,
analyzed and interpreted the data critically and wrote the manuscript. G.F.C. performed histological analysis. S.B.
contributed to data analyses. D.N. and P.P. performed real-time PCR and microarray analysis. M.R. contributed to
a critical revision of the manuscript. F.M. and M.D.C. contributed to supervising the study, writing and reviewing
the manuscript.
Conflicts of Interest: The authors declare no conflict of interest. The funding sponsors had no role in the design of
the study; in the collection, analyses or interpretation of data; in the writing of the manuscript; nor in the decision
to publish the results.
References
1. Lim, S.; Oh, T.J.; Koh, K.K. Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic
disorders. Int. J. Cardiol. 2015, 201, 408–414. [CrossRef] [PubMed]
2. Harrison, S.A.; Day, C.P. Benefits of lifestyle modification in NAFLD. Gut 2007, 56, 1760–1769. [CrossRef]
[PubMed]
3. Paschos, P.; Tziomalos, K. Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications
for treatment. World J. Hepatol. 2012, 4, 327–331. [CrossRef] [PubMed]
4. Xu, Y.Z.; Zhang, X.; Wang, L.; Zhang, F.; Qiu, Q.; Liu, M.L.; Zhang, G.R.; Wu, X.L. An increased circulating
angiotensin II concentration is associated with hypoadiponectinemia and postprandial hyperglycemia in
men with nonalcoholic fatty liver disease. Intern. Med. 2013, 52, 855–861. [CrossRef] [PubMed]
5. Moreira de Macêdo, S.; Guimarães, T.A.; Feltenberger, J.D.; Sousa Santos, S.H. The role of renin-angiotensin
system modulation on treatment and prevention of liver diseases. Peptides 2014, 62, 189–196. [CrossRef]
[PubMed]
Nutrients 2017, 9, 492 12 of 13
6. Kurita, S.; Takamura, T.; Ota, T.; Matsuzawa-Nagata, N.; Kita, Y.; Uno, M.; Nabemoto, S.; Ishikura, K.;
Misu, H.; Ando, H.; et al. Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis
through its pleiotropic effects. Eur. J. Pharmacol. 2008, 588, 316–324. [CrossRef] [PubMed]
7. Wei, Y.; Rector, R.S.; Thyfault, J.P.; Ibdah, J.A. Nonalcoholic fatty liver disease and mitochondrial dysfunction.
World J. Gastroenterol. 2008, 14, 193–199. [CrossRef] [PubMed]
8. Husain, K.; Hernandez, W.; Ansari, R.A.; Ferder, L. Inflammation, oxidative stress and renin angiotensin
system in atherosclerosis. World J. Biol. Chem. 2015, 6, 209–217. [CrossRef] [PubMed]
9. Fargion, S.; Porzio, M.; Fracanzani, A.L. Nonalcoholic fatty liver disease and vascular disease: State-of-the-art.
World J. Gastroenterol. 2014, 20, 13306–13324. [CrossRef] [PubMed]
10. Stepanova, M.; Younossi, Z.M. Independent association between nonalcoholic fatty liver disease and
cardiovascular disease in the US population. Clin. Gastroenterol. Hepatol. 2012, 10, 646–650. [CrossRef]
[PubMed]
11. Targher, G.; Day, C.P.; Bonora, E. Risk of cardiovascular disease in patients with Nonalcoholic Fatty Liver
Disease. N. Engl. J. Med. 2010, 363, 1341–1350. [CrossRef] [PubMed]
12. Frantz, E.D.; Penna-de-Carvalho, A.; Batista Tde, M.; Aguila, M.B.; Mandarim-de-Lacerda, C.A. Comparative
effects of the renin-angiotensin system blockers on nonalcoholic fatty liver disease and insulin resistance in
C57BL/6 mice. Metab. Syndr. Relat. Disord. 2014, 12, 191–201. [CrossRef] [PubMed]
13. Fraga-Silva, R.A.; Savergnini, S.Q.; Montecucco, F.; Nencioni, A.; Caffa, I.; Soncini, D.; Costa-Fraga, F.P.;
De Sousa, F.B.; Sinisterra, R.D.; Capettini, L.A.; et al. Treatment with Angiotensin-(1-7) reduces inflammation
in carotid atherosclerotic plaques. Thromb. Haemost. 2014, 111, 736–747. [CrossRef] [PubMed]
14. Malhotra, N.; Beaton, M.D. Management of non-alcoholic fatty liver disease in 2015. World J. Hepatol. 2015, 7,
2962–2967. [CrossRef] [PubMed]
15. Kim, S.B.; Kang, O.H.; Lee, Y.S.; Han, S.H.; Ahn, Y.S.; Cha, S.W.; Seo, Y.S.; Kong, R.; Kwon, D.Y.
Hepatoprotective effect and synergism of bisdemethoycurcumin against MCD Diet-Induced Nonalcoholic
Fatty Liver Disease in mice. PLoS ONE 2016, 11. [CrossRef] [PubMed]
16. Patti, A.M.; Al-Rasadi, K.; Katsiki, N.; Banerjee, Y.; Nikolic, D.; Vanella, L.; Giglio, R.V.; Giannone, V.A.;
Montalto, G.; Rizzo, M. Effect of a Natural Supplement Containing Curcuma Longa, Guggul, and Chlorogenic
Acid in Patients With Metabolic Syndrome. Angiology 2015, 66, 856–861. [CrossRef] [PubMed]
17. Baldassano, S.; Amato, A.; Cappello, F.; Rappa, F.; Mulè, F. Glucagon-like peptide-2 and mouse intestinal
adaptation to a high-fat diet. J. Endocrinol. 2013, 217, 11–20. [CrossRef] [PubMed]
18. Baldassano, S.; Amato, A.; Rappa, F.; Cappello, F.; Mulè, F. Influence of endogenous glucagon like peptide-2
on lipid disorders in mice fed a high fat diet. Endoc. Res. 2016, 23, 1–8. [CrossRef] [PubMed]
19. Jawien´, J.; Nastałek, P.; Korbut, R. Mouse models of experimental atherosclerosis. J. Physiol. Pharmacol. 2004,
55, 503–517. [PubMed]
20. Nuzzo, D.; Picone, P.; Baldassano, S.; Caruana, L.; Messina, E.; Marino Gammazza, A.; Cappello, F.; Mulè, F.;
Di Carlo, M. Insulin Resistance as Common Molecular Denominator Linking Obesity to Alzheimer’s Disease.
Curr. Alzheimer Res. 2015, 12, 723–735. [CrossRef] [PubMed]
21. Amato, A.; Baldassano, S.; Caldara, G.; Mulè, F. Neuronostatin: Peripheral site of action in mouse stomach.
Peptides 2015, 64, 8–13. [CrossRef] [PubMed]
22. Liang, W.; Menke, A.L.; Driessen, A.; Koek, G.H.; Lindeman, J.H.; Stoop, R.; Havekes, L.M.; Kleemann, R.;
van den Hoek, A.M. Establishment of a general NAFLD scoring system for rodent models and comparison
to human liver pathology. PLoS ONE 2014, 9. [CrossRef] [PubMed]
23. Frediani Brant, N.M.; Mourão Gasparotto, F.; de Oliveira Araújo, V.; Christian Maraschin, J.; Lima Ribeiro
Rde, C.; Botelho Lourenço, E.L.; Cardozo Junior, E.L.; Gasparotto Junior, A. Cardiovascular protective
effects of Casearia sylvestris Swartz in Swiss and C57BL/6 LDLr-null mice undergoing high fat diet.
J. Ethnopharmacol. 2014, 154, 419–427. [CrossRef] [PubMed]
24. Balzan, S.; Hernandes, A.; Reichert, C.L.; Donaduzzi, C.; Pires, V.A.; Gasparotto, A., Jr.; Cardozo, E.L., Jr.
Lipid-lowering effects of standardized extracts of Ilex paraguariensis in high-fat-diet rats. Fitoterapia 2013,
86, 115–122. [CrossRef] [PubMed]
25. Gibbons, S. An overview of plant extracts as potential therapeutics. Expert. Opin. Ther. Pat. 2003, 13, 489–497.
[CrossRef]
26. Sahebkar, A. Why it is necessary to translate curcumin into clinical practice for the prevention and treatment
of metabolic syndrome? Biofactors 2013, 39, 197–208. [CrossRef] [PubMed]
Nutrients 2017, 9, 492 13 of 13
27. Salamone, F.; Galvano, F.; Cappello, F.; Mangiameli, A.; Barbagallo, I.; Li Volti, G. Silibinin modulates lipid
homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis.
Transl. Res 2012, 159, 477–486. [CrossRef] [PubMed]
28. Nohr, L.A.; Rasmussen, L.B.; Straand, J. Resin from the mukul myrrh tree, guggul, can it be used for treating
hypercholesterolemia? A randomized, controlled study. Complement. Ther. Med. 2009, 17, 16–22. [CrossRef]
29. Mubarak, A.; Hodgson, J.M.; Considine, M.J.; Croft, K.D.; Matthews, V.B. Correction to Supplementation of
a high-fat diet with chlorogenic acid is associated with insulin resistance and hepatic lipid accumulation in
mice. J. Agric. Food Chem. 2013, 61, 4371–4378. [CrossRef] [PubMed]
30. Russo, F.; Riezzo, G.; Chiloiro, M.; De Michele, G.; Chimienti, G.; Marconi, E.; D’Attoma, B.; Linsalata, M.;
Clemente, C. Metabolic effects of a diet with inulin-enriched pasta in healthy young volunteers.
Curr. Pharm. Des. 2010, 16, 825–831. [CrossRef] [PubMed]
31. Chalasani, N.; Wilson, L.; Kleiner, D.E.; Cummings, O.W.; Brunt, E.M. Relationship of steatosis grade and
zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease.
J. Hepatol. 2008, 48, 829–834. [CrossRef] [PubMed]
32. Corey, K.E.; Chalasani, N. Management of dyslipidemia as a cardiovascular risk factor in individuals with
nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2014, 12, 1077–1084. [CrossRef] [PubMed]
33. Atshaves, B.P.; Martin, G.G.; Hostetler, H.A.; McIntosh, A.L.; Kier, A.B.; Schroeder, F. Liver fatty acid-binding
protein and obesity. J. Nutr. Biochem. 2010, 21, 1015–1032. [CrossRef] [PubMed]
34. Westerbacka, J.; Kolak, M.; Kiviluoto, T.; Arkkila, P.; Sirén, J.; Hamsten, A.; Fisher, R.M.; Yki-Järvinen, H.
Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and
inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes 2007, 56,
2759–2765. [CrossRef] [PubMed]
35. Kotronen, A.; Seppänen-Laakso, T.; Westerbacka, J.; Kiviluoto, T.; Arola, J.; Ruskeepää, A.L.; Oresic, M.;
Yki-Järvinen, H. Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide
concentrations are increased in the nonalcoholic human fatty liver. Diabetes 2009, 58, 203–208. [CrossRef]
[PubMed]
36. Miyazaki, M.; Dobrzyn, A.; Sampath, H.; Lee, S.H.; Man, W.C.; Chu, K.; Peters, J.M.; Gonzalez, F.J.;
Ntambi, J.M. Reduced adiposity and liver steatosis by stearoyl-CoA desaturase deficiency are independent of
peroxisome proliferator-activated receptor-alpha. J. Biol. Chem. 2004, 279, 35017–35024. [CrossRef] [PubMed]
37. Cohen, P.; Miyazaki, M.; Socci, N.D.; Hagge-Greenberg, A.; Liedtke, W.; Soukas, A.A.; Sharma, R.;
Hudgins, L.C.; Ntambi, J.M.; Friedman, J.M. Role for stearoyl-CoA desaturase-1 in leptin-mediated weight
loss. Science 2002, 297, 240–243. [CrossRef] [PubMed]
38. Kandhi, R.; Bobbala, D.; Yeganeh, M.; Mayhue, M.; Menendez, A.; Ilangumaran, S. Negative regulation of
the hepatic fibrogenic response by suppressor of cytokine signaling 1. Cytokine 2016, 82, 58–69. [CrossRef]
[PubMed]
39. Klein, T.; Fujii, M.; Sandel, J.; Shibazaki, Y.; Wakamatsu, K.; Mark, M.; Yoneyama, H. Linagliptin alleviates
hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis. Med. Mol. Morphol.
2014, 47, 137–149. [CrossRef] [PubMed]
40. Whitman, S.C. A practical approach to using mice in atherosclerosis research. Clin. Biochem. Rev. 2004, 25,
81–93. [PubMed]
41. Villanova, N.; Moscatiello, S.; Ramilli, S.; Bugianesi, E.; Magalotti, D.; Vanni, E.; Zoli, M.; Marchesini, G.
Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005,
42, 473–480. [CrossRef] [PubMed]
42. Wieckowska, A.; Papouchado, B.G.; Li, Z.; Lopez, R.; Zein, N.N.; Feldstein, A.E. Increased hepatic and
circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2008, 103,
1372–1379. [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
